VYNE
Yarrow Bioscience, Inc.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 3 added (0 new), 2 trimmed or exited.
- Short sellersBUILDING
Short interest +76.3% to 184.0K shares. 1.0 days to cover, ≈0.6% of shares.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | $77.4K |
| UBS Group AG | TRIM | $38.1K |
| NORTHERN TRUST CORP | ADD | $28.4K |
| JANE STREET GROUP, LLC | TRIM | $26.7K |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $15.2K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $192.8K |
| UBS Group AG | DOUBLED | $107.5K |
| JANE STREET GROUP, LLC | ADD | $57.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Jul 2025| Date | Firm | Rating |
|---|---|---|
| Jul 30, 2025 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Apr 25, 2025 | HC Wainwright & Co. MAINTAIN | Buy |
| Mar 6, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Feb 19, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Jan 14, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Jan 6, 2025 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jul 23, 2026 | Zeronda Tyler CHIEF FINANCIAL OFFICER | TAX W/H | $20.2K |
| Jul 23, 2026 | Stuart Iain CHIEF SCIENTIFIC OFFICER | TAX W/H | $13.8K |
| Jul 23, 2026 | Domzalski David PRESIDENT AND CEO | TAX W/H | $71.3K |
| Jul 23, 2026 | Harsch Mutya CHIEF LEGAL OFFICER AND GC | TAX W/H | $20.2K |
| Jun 30, 2026 | Domzalski David PRESIDENT AND CEO | TAX W/H | $7.9K |
| Jun 30, 2026 | Harsch Mutya CHIEF LEGAL OFFICER AND GC | TAX W/H | $2.3K |
| Jun 30, 2026 | Stuart Iain CHIEF SCIENTIFIC OFFICER | TAX W/H | $1.5K |
| Jun 30, 2026 | Zeronda Tyler CHIEF FINANCIAL OFFICER | TAX W/H | $2.3K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | -$55.00 | -$55.00–-$55.00 | +0.0% | $0.00 |
| Next FY | -$82.50 | -$82.50–-$82.50 | +0.0% | $0.00 |
Short side
FINRA· Jul 15, 2026| Jul 24, 2026 | Resumption Scheduled | Resumed |
SecBot reports
6 filings · 0 bullish · 0 bearish · 6 neutral- NEUTRAL SC 13GOct 7, 2026
Bellevue Group AG, a Swiss asset manager, filed a Schedule 13G disclosing a 10.6% passive stake in…
Monitor for any subsequent amendments to this 13G for stake changes, or a potential conversion to a 13D if Bellevue's intent changes. The 10.6% position is large enough to be a meaningful holder…
- NEUTRAL 3Jul 29, 2026
Steven Hoerter filed a Form 3 initial statement of beneficial ownership after Yarrow Bioscience…
This filing is administrative and contains no trading signal. Monitor future insider Form 4 filings for open-market purchases or sales by Hoerter, which would provide actionable information.
- NEUTRAL 8-KJul 21, 2026
VYNE Therapeutics filed an 8-K announcing a 1-for-50 reverse stock split and a $17.3 million…
Traders should note the ex-dividend date of July 24 and the due bill period (July 21-23) for the special dividend. The reverse split will adjust the stock price upward by 50x. After the merger…
- NEUTRAL 425, 8-KJul 14, 2026
VYNE Therapeutics filed an 8-K (Item 7.01) furnishing an investor presentation by Yarrow…
The merger is on track for the July 24 close and July 16 special meeting. Monitor stockholder vote outcome and any last-minute deal amendments. Post-close, the combined entity (YARW) will be a…
All VYNE filing & press-release reports (6)
- SC 13G reportOct 7, 2026
- 3 reportJul 29, 2026
- 8-K reportJul 21, 2026
- 425, 8-K reportJul 14, 2026
- 425, 8-K reportJul 10, 2026
- EFFECT reportJun 17, 2026